NEW YORK (GenomeWeb) ─ Response Genetics entered the next-generation sequencing-based diagnostics market this week with the launch of a non-small cell lung cancer panel proprietary to the Knight Diagnostic Laboratories at Oregon Health & Science University.

The test, according to OHSU's website, operates on an Ion Torrent PGM platform and gauges a number of genetic alterations known to impact lung cancer patients' response to different treatments, as well as markers that are being studied in investigational drug trials.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: human cytomegalovirus diversity, patterns of homologous recombination in E. coli, and more.

US lawmakers are considering eliminating the medical devices tax that is part of the Affordable Care Act.

Two research teams in China home in on a gene that gives rice a long, slender shape.

Marcia McNutt, the editor-in-chief of Science, has been nominated to become president of the US National Academy of Sciences.